FDA has granted fast track designation to Biohaven’s Taldefgrobep Alfa for the treatment of…
Biohaven Ltd. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the…
Read More...
Read More...